Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16495829 | 0.87 | HPGDS (0.57) | KMT2AHPGDSKDM1A | |
| SCHEMBL16495418 | 0.82 | GABRA5 (0.61) | GABRA5HPGDS | |
| SCHEMBL12775215 | 0.77 | HPGDS (0.58) | GABRA5KMT2AHPGDSHSD17B10USP30 | |
| SCHEMBL14190793 | 0.77 | HPGDS (0.58) | GABRA5KMT2AHPGDSUSP30 | |
| SCHEMBL16495494 | 0.76 | HPGDS (0.51) | GABRA5HPGDS | |
| SCHEMBL21880646 | 0.75 | RAB9A (0.53) | KMT2AHSD17B10 | |
| SCHEMBL12318668 | 0.75 | RAB9A (0.53) | KMT2AHSD17B10 | |
| SCHEMBL16495430 | 0.75 | HPGDS (0.50) | GABRA5HPGDS | |
| SCHEMBL16495485 | 0.75 | SRC (0.50) | HPGDSUSP30 | |
| SCHEMBL16495534 | 0.75 | HPGD (0.64) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | CRAWFORTH JAMES MICHAEL (GB) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306597-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | GABRA5 1938/4885KMT2A 3206/4885HPGDS 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.